Abstract:Fibrosis, defined as the abnormal deposition of extracellular matrix (ECM), represents the concluding pathological outcome in a number of inflammatory, immune-mediated and metabolic diseases. Recent single cell RNA-sequencing studies have highlighted the diversity and functional heterogeneity of fibroblast populations in multiple fibrotic conditions. These include a novel pathogenic population of high collagen-producing fibroblasts, characterised by expression of the secreted glycoprotein, collagen triple helix repeat containing 1 (CTHRC1). The cardinal pro-fibrotic mediator TGF-β1 has been widely implicated in promoting fibrogenesis and is a potent inducer of CTHRC1 and COL1A1 expression. In addition to the canonical Smad signalling pathway, TGF-β1-induced collagen I production is under critical regulatory control by the mTORC1/4E-BP1 signalling hub. Using pharmacological inhibition in combination with gene-editing approaches, we now demonstrate that the role of the mTORC1 axis extends to the regulation of over a third of all TGF-β1 regulated matrisome genes. We provide further evidence that the global transcriptome of TGF-β1-stimulated fibroblasts in vitro matches that of a subpopulation of the high collagen expressing CTHRC1+ pathological fibroblast population in the IPF lung. In contrast, the TGF-β1 induced transcriptome of fibroblasts in which mTORC1 signalling is disrupted (by RPTOR gene editing using CRISPR-Cas9) does not map to any fibroblast population present in human control or fibrotic lung. Using the novel and selective mTORC1 inhibitor RMC-5552, we further demonstrate a direct functional link between mTORC1 signalling and the acquisition of key marker genes which define the CTHRC1+ fibroblast population in IPF. These data demonstrate, for the first time, a critical role for the mTORC1 signalling hub in determining the transcriptional identity of the CTHRC1+ pathological fibroblast population and provide strong scientific support for targeting mTORC1 as a therapeutic strategy in IPF and potentially other fibrotic conditions associated with dysregulated TGF-β1 signalling in the fibrotic niche.

What problem does this paper attempt to address?

The problem this paper attempts to address is: determining the critical role of the mTORC1 signaling axis in defining the transcriptomic characteristics of CTHRC1+ pathological fibroblasts. Specifically, the researchers aim to explore how the mTORC1 signaling pathway regulates TGF-β1-induced extracellular matrix (ECM) gene expression through pharmacological inhibition and gene editing methods, and further validate the functional role of mTORC1 in the CTHRC1+ pathological fibroblast population. ### Main Research Questions: 1. **The role of the mTORC1 signaling axis in TGF-β1-induced ECM gene expression**: - Researchers explored the regulatory role of the mTORC1 signaling axis in TGF-β1-induced ECM gene expression through pharmacological inhibition and gene editing methods. - Using mTORC1 inhibitors (such as AZD8055 and RMC-5552) and partial mTORC1 inhibitors (such as rapamycin), they analyzed the effects of these inhibitors on TGF-β1-induced gene expression. 2. **The role of the mTORC1 signaling axis in defining the transcriptomic characteristics of CTHRC1+ pathological fibroblasts**: - Using CRISPR-Cas9 gene editing technology, they knocked out key components of mTORC1 and mTORC2 (RPTOR and RICTOR) to study the contributions of these two complexes in TGF-β1-induced transcriptomic changes. - They integrated the gene-edited fibroblasts with publicly available single-cell RNA sequencing (scRNA-Seq) datasets to explore the functional role of the mTORC1 signaling axis in the CTHRC1+ pathological fibroblast population. 3. **The potential of the mTORC1 signaling axis as an anti-fibrotic therapeutic target**: - Using the selective mTORC1 inhibitor RMC-5552, they studied its effects on TGF-β1-induced collagen synthesis and deposition, as well as the expression of CTHRC1+ fibroblast marker genes. - These experimental results provide scientific evidence for considering mTORC1 as a potential therapeutic target for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. ### Research Background: - **Fibrosis**: Fibrosis is a pathological process characterized by abnormal deposition of the extracellular matrix (ECM), commonly seen in various chronic inflammatory, immune-mediated, and metabolic diseases. - **TGF-β1**: Transforming growth factor β1 (TGF-β1) is known as the most potent pro-fibrotic cytokine, regulating ECM gene expression through the classical Smad signaling pathway and the non-classical mTORC1/4E-BP1 signaling pathway. - **CTHRC1+ Fibroblasts**: Recent single-cell RNA sequencing studies have shown that CTHRC1+ fibroblasts are a pathological fibroblast subpopulation with high collagen production, playing a key role in various fibrotic diseases. ### Research Significance: - This study is the first to reveal the critical role of the mTORC1 signaling axis in defining the transcriptomic characteristics of CTHRC1+ pathological fibroblasts, providing a theoretical basis for developing anti-fibrotic therapeutic strategies targeting mTORC1.

Critical role for the TGF-β1/mTORC1 signalling axis in defining the transcriptional identity of CTHRC1+ pathologic fibroblasts

CTHRC1: An Emerging Hallmark of Pathogenic Fibroblasts in Lung Fibrosis

ATF4 and mTOR regulate metabolic reprogramming in TGF-β-treated lung fibroblasts

TGF{beta} drives fibrotic remodeling via modulation of homeostatic and pathological fibroblast populations in a murine model of pulmonary fibrosis

The matricellular protein CCN1 enhances TGF‐β1/SMAD3‐dependent profibrotic signaling in fibroblasts and contributes to fibrogenic responses to lung injury

The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis

O-GlcNAc transferase regulates collagen deposition and fibrosis resolution in idiopathic pulmonary fibrosis

Rictor/mTORC2 signaling mediates TGFβ1-induced fibroblast activation and kidney fibrosis

Multiscale single-cell assessment of the fibrotic niche in idiopathic pulmonary fibrosis

TGFβ1-RCN3-TGFBR1 loop facilitates pulmonary fibrosis by orchestrating fibroblast activation

Sfrp1 inhibits lung fibroblast invasion during transition to injury-induced myofibroblasts

Regulation of extracellular matrix gene expression and biosynthetic pathways in pulmonary fibroblasts by HSF1

Transforming Growth Factor-β Receptor Type I-dependent Fibrogenic Gene Program is Mediated Via Activation of Smad1 and ERK1/2 Pathways

METTL3‐Dependent YTHDF2 Mediates TSC1 Expression to Regulate Alveolar Epithelial Mesenchymal Transition and Promote Idiopathic Pulmonary Fibrosis

TGF-β and the Tissue Microenvironment: Relevance in Fibrosis and Cancer

IL11-mediated stromal cell activation may not be the master regulator of pro-fibrotic signaling downstream of TGFβ

Altered AP-1, RUNX, and EGR chromatin dynamics drive fibrotic lung disease

Leukemia inhibitory factor (LIF) receptor amplifies pathogenic activation of fibroblasts in lung fibrosis

Targeted regulation of fibroblast state by CRISPR-mediated CEBPA expression

Systematic analyses identify the anti-fibrotic role of lncRNA TP53TG1 in IPF

A Thy-1–negative immunofibroblast population emerges as a key determinant of fibrotic outcomes to biomaterials